Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 25 02:20PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.20 Insider Own34.85% Shs Outstand21.38M Perf Week-2.94%
Market Cap130.70M Forward P/E- EPS next Y-4.08 Insider Trans0.11% Shs Float20.79M Perf Month-12.85%
Income-27.92M PEG- EPS next Q-0.33 Inst Own59.79% Short Float10.71% Perf Quarter-21.53%
Sales2.00M P/S65.35 EPS this Y35.34% Inst Trans- Short Ratio3.76 Perf Half Y-27.38%
Book/sh5.95 P/B0.69 EPS next Y-137.09% ROA-25.18% Short Interest2.23M Perf Year-
Cash/sh6.07 P/C0.67 EPS next 5Y- ROE-26.35% 52W Range2.13 - 20.71 Perf YTD-24.43%
Dividend Est.- P/FCF- EPS past 5Y-16.23% ROI-14.69% 52W High-80.22% Beta-
Dividend TTM- Quick Ratio43.12 Sales past 5Y0.00% Gross Margin96.55% 52W Low92.30% ATR (14)0.40
Dividend Ex-Date- Current Ratio43.12 EPS Y/Y TTM- Oper. Margin-1637.15% RSI (14)41.68 Volatility7.39% 9.17%
Employees10 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin-1395.90% Recom1.00 Target Price39.20
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q25.92% Payout- Rel Volume0.35 Prev Close4.20
Sales Surprise- EPS Surprise40.52% Sales Q/Q- EarningsMay 15 BMO Avg Volume591.99K Price4.10
SMA20-13.48% SMA50-9.28% SMA200-31.41% Trades Volume156,193 Change-2.48%
Date Action Analyst Rating Change Price Target Change
May-02-24Initiated H.C. Wainwright Buy $32
Mar-25-24Initiated Leerink Partners Outperform $26
Aug-08-23Initiated TD Cowen Outperform
Aug-08-23Initiated Piper Sandler Overweight $67
Aug-08-23Initiated JMP Securities Mkt Outperform $30
Aug-08-23Initiated Goldman Buy $33
Jun-10-24 08:00AM
Jun-06-24 05:00AM
May-16-24 08:00AM
May-15-24 12:53PM
08:00AM Loading…
May-07-24 08:00AM
May-06-24 08:00AM
Apr-22-24 08:00AM
Mar-27-24 04:01PM
Mar-25-24 07:00AM
Feb-29-24 08:00AM
Jan-25-24 08:58PM
Jan-23-24 05:45PM
Jan-22-24 11:10PM
07:00AM Loading…
Dec-04-23 08:00AM
Nov-28-23 08:00AM
Nov-22-23 08:00AM
Nov-13-23 08:00AM
Nov-10-23 08:30AM
Oct-24-23 11:00AM
Oct-18-23 04:05PM
Sep-27-23 04:05PM
Aug-29-23 10:21AM
Aug-21-23 04:02PM
Aug-15-23 04:04PM
Aug-08-23 10:02AM
Jul-20-23 04:05PM
Jul-13-23 09:10PM
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Happel DavidPresident & CEOMar 26 '24Buy5.2712,10063,731639,200Mar 28 04:08 PM
Happel DavidPresident & CEODec 07 '23Buy4.101,6006,560627,100Dec 08 04:05 PM
Happel DavidPresident & CEONov 16 '23Buy2.355901,386590Nov 20 09:59 PM
Kemble GeorgeExecutive ChairmanSep 07 '23Option Exercise0.795,6304,4485,630Sep 08 04:15 PM
SEIDENBERG BETH CDirectorJul 18 '23Buy16.0046,875750,00046,875Jul 20 04:20 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerJul 18 '23Buy16.0030,000480,0003,850,275Jul 20 06:56 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerJul 18 '23Sale16.0066210,5923,820,275Jul 20 06:56 PM